An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Novo Nordisk A/S1,889 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.

Study Type

OBSERVATIONAL

Enrollment

1,889

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Prescribed at the discretion of the physician

insulin detemirDRUG

Prescribed at the discretion of the physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Macedonian people with diabetes mellitus (Type 1 or Type 2)

Locations (1)

Novo Nordisk Investigational Site

Skopje, North Macedonia

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Percentage of subjects reaching HbA1c target of maximum 7.0%

Postprandial plasma glucose (PPG)

Fasting plasma glucose (FPG)

Change in body weight

Incidence of adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.